Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Healthcare Antitrust Year-In-Review Webinar
Webinar
Antitrust
Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2026
Axinn Viewpoints
Antitrust
Axinn Announces Nominations for the Concurrences 2026 Antitrust Writing Awards
Awards & Recognitions
Antitrust
SABA North America Corporate Counsel Retreat 2026
Speaking Engagement
Antitrust
Axinn Promotes Lindsey Strang Aberg, Rebecca L. Clegg, Allison Vissichelli, and Eva Yung to Partner; Ricardo Camposanto, Danielle D. Irvine, and Josh Jowdy to Counsel
News
Antitrust